New Market - September 19, 2018
SenzaGen launches in vitro airway allergy test
The company will launch GARDair, the first in vitro test for airway allergies at ESTIV2018, the 20th International Congress on In Vitro Toxicology. Removing the need for animal testing and opening a completely new market, GARDair is based on the company’s GARD technology platform, it states. Using genetic biomarkers, GARDair tests whether substances and chemicals […]
New Market - September 12, 2018
Acarix to the Austrian market
The company reports first sales in Austria for its CADScor System for early rule-out of CAD. “By using the unique technology provided by Acarix and the CADScor System I can limit the number of patients that will be referred to coronary angiography. This will help shorten waiting lists and add value for both patients and the healthcare system. […]
New Market - August 30, 2018
Orexo’s Zubsolv launched in the EU
The company announced in June that its partner Mundipharma has initiated the launch of Zubsolv (buprenorphine and naloxone sublingual tablet), for use in the treatment of opioid dependence, in the EU. The launch is triggering a milestone payment of EUR 3 million (approx. SEK 30.6 million) from Mundipharma, reports the company. “Taking the step out in […]
MedTech Business - July 25, 2018
Dignitana expands in Italy
The company has registered Dignitana S.r.l as a new entity in Italy, a wholly-owned subsidiary of Dignitana AB. The entity will function under the leadership of Dignitana AB and with this registration the company can now finalize contracts for the sale of 3 machines in Italy. “We are excited to announce the registration of Dignitana S.r.l […]
New Market - May 22, 2018
AstraZeneca’s Lokelma approved in the US
The US Food and Drug Administration has approved Lokelma (sodium zirconium cyclosilicate), formerly ZS-9, for the treatment of adults with hyperkalaemia,a serious condition characterised by elevated potassium levels in the blood associated with cardiovascular, renal and metabolic diseases. The risk of hyperkalaemia increases significantly for patients with chronic kidney disease (CKD) and for those who take common […]
New Market - April 5, 2018
Novo’s Ozempic approved in Japan
Novo Nordisk has announced that the Japanese Ministry of Health, Labour and Welfare has approved Ozempic (semaglutide), a new once-weekly analogue of human glucagon-like peptide-1 (GLP-1), for the treatment of adults with type 2 diabetes. The approval of Ozempic in Japan is based on results from the SUSTAIN clinical trial programme, which involved more than […]
